Jan 14, 2026
How do FDA‑approved Alzheimer’s drugs perform in randomized trials on cognition and disease progression?
Randomized, double‑blind trials of the newest FDA‑approved Alzheimer’s drugs—principally the anti‑amyloid monoclonal antibodies lecanemab (Leqembi) and donanemab (Kisunla)—have demonstrated statistica...